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Superficial thrombophlebitis (ST) or superficial venous thrombosis is a relatively common inflammatory 
thrombotic disorder, and involves the development of a thrombus in a superficial vein located near the 
surface of the skin. Signs and symptoms include pain and a reddened, warm and tender cord extending 
along the vein as well as erythema and oedema in the surrounding tissue. Patients with ST are at risk of 
developing more serious conditions including deep vein thrombosis (DVT), pulmonary embolism (PE) 
and venous thromboembolism (VTE) (Quenet, 2003, Unno, 2002). 
The majority of cases of ST develop in varicose veins on the lower limbs. Other risk factors include 
immobilisation, trauma, postoperative states, pregnancy, puerperium (the period immediately following 
childbirth), active malignancy, autoimmune diseases, use of oral contraceptive pills or hormonal 
replacement therapy, advanced age, obesity and a history of previous venous thromboembolism (de 
Moerloose, 1998). 
There is a lack of consensus on the best practice for management of patients with ST and current 
strategies include surgery, elastic stockings and non-steroidal anti-inflammatory drugs which are aimed 
at reducing inflammation and pain, as well as the use of several anti-coagulant medications. 
 
 Objective/s:  
 
The primary objective of this review was to assess the efficacy and safety of topical, medical and 
surgical treatments for ST of the leg, related to the improvement of local symptoms and reduction of the 
complications associated with thromboembolisms.  
NB: This was the second update of a review originally conducted in 2007 (Di Nisio et al, 2007). 
 
 Intervention/Methods:  
 
The review included randomised controlled trials (RCTs) that evaluated topical, medical and surgical 
treatments for ST of the legs. The participants included hospitalised and non-hospitalised patients with a 
diagnosis of ST in the lower extremities. 
The primary outcomes included: 
1. Symptomatic VTE; 
2. Major bleeding. 
The secondary outcome measures considered were: 
 Symptomatic PE; 
 Symptomatic DVT or progression of ST into DVT; 
 Extension of ST; 
 Recurrence of ST; 
 Signs and symptoms; 
 Quality of life; 
 Mortality; 
 Adverse effects of treatment; 
 Arterial thromboembolic events. 
 Results: 
 
There were 33 studies included in this review, representing a total of 7296 participants. The 
interventions and comparisons varied widey between the studies. In a large placebo-controlled RCT (n = 
3002) the administration of sub-cutaneous fondaparinux was associated with a significant reduction in 
symptomatic VTE and ST recurrence compared to placebo (moderate-quality evidence). In a smaller 
study (n = 472) that compared fondaparinux to rivaroxaban, a non-significant reduction of symptomatic 
VTE was identified. No major episodes of bleeding were reported in either study. 
The results of a study that compared low molecular weight heparin (LMWH) to a placebo showed a 
reduction in the extension and recurrence of ST (low-quality evidence) and no significant effects on 
symptomatic  VTE or major bleeding (low-quality evidence).  
Overall the use of topical treatments was found to improve local symptoms. Surgical treatment 
combined with elastic stockings was associated with a lower VTE rate and ST progression compared to 




The authors reported that the prophylactic use of fondaparinux for 45 days was a valid treatment 
strategy for the majority of patients with ST of the legs. The results for topical treatment or surgery was 
too limited for conclusions to be drawn on their efficacy in preventing progression to VTE  
 
 Implications for Practice: 
 
Nurses should be aware that patients with ST of the legs are at risk of developing more serious 
disorders including DVT, PE and VTE  and should ensure that they monitor them appropriately for any 
signs and symptoms of deterioration. They should also ensure that preventative actions are in place to 
mitigate these risks. 
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